Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation.

Funke-Chambour, Manuela; Kewalramani, Namrata; Machahua, Carlos; Poletti, Venerino; Wells, Athol U; Cadranel, Jacques (2022). Reply to: Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation. ERJ Open Research, 8(4) European Respiratory Society 10.1183/23120541.00469-2022

[img]
Preview
Text
00469-2022.full.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (210kB) | Preview

The divergent views on lung cancer treatments in fibrosing lung patients reflect differences due to variable side-effect incidences in different countries and among ethnicities. International efforts are needed to better define treatment approaches.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Mu50 > Forschungsgruppe Pneumologie (Erwachsene)
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology

UniBE Contributor:

Funke-Chambour, Manuela, Kewalramani, Namrata Murli, Machahua Huamani, Carlos Esteban

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2312-0541

Publisher:

European Respiratory Society

Language:

English

Submitter:

Pubmed Import

Date Deposited:

20 Jan 2023 09:38

Last Modified:

12 May 2023 12:40

Publisher DOI:

10.1183/23120541.00469-2022

PubMed ID:

36655227

BORIS DOI:

10.48350/177697

URI:

https://boris.unibe.ch/id/eprint/177697

Actions (login required)

Edit item Edit item
Provide Feedback